Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Reaffirmed as “Sector Perform” by Royal Bank Of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “sector perform” rating reaffirmed by research analysts at Royal Bank Of Canada in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $737.00 price objective on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective would suggest a potential downside of 1.69% from the company’s previous close.

REGN has been the subject of a number of other reports. Piper Sandler reduced their target price on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research report on Thursday, July 9th. Citigroup upped their target price on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Cantor Fitzgerald upped their target price on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, September 21st. Fourteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $802.18.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $2.55 during trading hours on Tuesday, hitting $749.70. 439,458 shares of the stock traded hands, compared to its average volume of 828,493. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The firm’s 50 day moving average price is $781.41 and its 200-day moving average price is $720.99. The stock has a market capitalization of $77.19 billion, a price-to-earnings ratio of 18.53, a P/E/G ratio of 1.54 and a beta of 0.20. Regeneron Pharmaceuticals has a 1 year low of $541.00 and a 1 year high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same period in the previous year, the firm earned $12.81 EPS. The business’s quarterly revenue was up 16.7% on a year-over-year basis. As a group, equities analysts expect that Regeneron Pharmaceuticals will post 44.25 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Arthur Ryan sold 200 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the transaction, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the transaction, the director directly owned 603 shares of the company’s stock, valued at approximately $512,550. This trade represents a 39.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 4,146 shares of company stock valued at $3,432,488. Corporate insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Western Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $26,000. SHP Wealth Management purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $26,000. Titan Wealth CI Ltd acquired a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $29,000. MCF Advisors LLC raised its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 15 shares during the period. Finally, Mowery & Schoenfeld Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the second quarter valued at $29,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Biohaven entered a clinical supply agreement to evaluate its cancer candidate BHV-1530 in combination with Regeneron’s Libtayo in patients with solid tumors, with enrollment underway. The collaboration could support Libtayo’s development and expand Regeneron’s oncology pipeline. Why Did Regeneron Pharmaceuticals Stock Drop Today?
• Neutral Sentiment: Regeneron’s third-quarter results are expected on October 30. Investors will likely focus on Eylea sales, broader pipeline progress and whether the company can maintain its strong earnings trajectory after its latest reported quarter beat expectations on both earnings and revenue. Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?
• Neutral Sentiment: Royal Bank of Canada reaffirmed its “sector perform” rating and assigned a $737 price target, indicating limited near-term upside based on its valuation view. Separately, a value comparison with Illumina is drawing attention to REGN’s investment appeal, but does not represent a new company-specific catalyst. Royal Bank of Canada Rating REGN or ILMN Value Comparison
• Negative Sentiment: Kodiak Sciences reported positive Phase 3 DAYBREAK results for Zenkuda and tabirafusp alfa tedromer in wet age-related macular degeneration. The candidates met primary endpoints against Eylea while being administered approximately every six months, compared with Eylea’s roughly eight-week dosing schedule. The data raise the possibility of meaningful future competition for Regeneron’s key eye-care franchise and triggered the recent pullback in REGN shares. What Does Regeneron Need to Prove in Eye Disease?

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.